The Institut Paoli-Calmettes (IPC), a leading cancer center in Marseille, recently marked its centennial with a ceremony recognizing a century of dedication to patient care and cancer research. Celebrations, presided over by regional leaders, highlighted the institute’s evolution from its early roots in post-war France to its current status as a European center of excellence treating approximately 12,000 new patients annually. As the Provence-Alpes-Côte d’Azur region confronts particularly high cancer incidence and mortality rates, the IPC’s continued innovation and regional partnerships are vital to improving outcomes.
The Institut Paoli-Calmettes (IPC), a leading regional cancer center, recently celebrated its 100th anniversary with an official ceremony presided over by Renaud Muselier, President of the Provence-Alpes-Côte d’Azur Region. The event was attended by Simon Babre, Prefect of the Var and Chairman of the IPC’s Board of Directors, Sylvain Di Giovanni, a departmental counselor delegated to health representing Martine Vassal, and Caroline Chassin, Deputy Director General of the institute.
Renaud Muselier highlighted the institute’s unique history and its deep connection to the evolution of cancer care in France during the anniversary event. He paid tribute to the founding figures who shaped the institution, including General de Gaulle, who formalized the status of cancer centers in 1948, Professor Jean Paoli, who led the institute from 1952 to 1970 and oversaw its establishment in Sainte-Marguerite, and Irène Calmettes, a nurse dedicated to cancer treatment in Marseille as early as 1927. Recognizing the historical milestones of cancer treatment is crucial for understanding the progress made in patient care and research.
A Regional Hub for Comprehensive Cancer Care
Table of Contents
A century after its founding, the Institut Paoli-Calmettes remains a major university hospital center. Today, the institute operates across five buildings, manages an annual budget of €370 million (approximately $395 million USD), and holds European recognition since 2019. Each year, the IPC treats 12,000 new patients and provides over 100,000 consultations. The center is equipped with 277 beds, 12 operating rooms, four radiotherapy accelerators, and two surgical robots, all staffed by a team of 2,144 employees, including 397 physicians. Muselier emphasized the institution’s strategic importance, calling it “a jewel of the region” and a national reference for medical and scientific expertise.
Regional Health Challenges
Muselier also addressed concerning health statistics within the Provence-Alpes-Côte d’Azur region. Approximately 12,000 residents die from cancer annually, representing 27% of all deaths in the area. Women in the region experience the highest cancer incidence rate in France. Contributing factors include smoking, alcohol consumption, and delays in screening – with breast cancer screening rates lagging by 10 percentage points and colorectal cancer screening by 4 percentage points. These statistics underscore the need for increased public health initiatives focused on prevention and equitable access to care.
Investing in Research and Early Detection
In response to these challenges, the Sud Region has implemented a comprehensive strategy. The region launched its first Regional Cancer Plan in 2017, a unique initiative at the time, supported by a €28 million (approximately $30 million USD) investment. A second plan, launched in 2022 with a budget of €40 million (approximately $43 million USD), focuses on four key priorities: establishing the Sud Region as a global research hub, accelerating innovation and economic development, strengthening prevention and screening programs, and supporting healthcare professionals and patients.
Several projects were announced or confirmed during the anniversary ceremony. These include the Mammobile, a mobile mammography unit designed to reach remote areas, developed in partnership with the Sainte-Catherine Institute and the Antoine Lacassagne Centre. Another key initiative is the Interception program, which aims to provide personalized support to vulnerable populations through diagnostics, health workshops, and preventative care.
IPC: A Leader in Cutting-Edge Research
Research remains central to the regional strategy. The IPC is internationally recognized, particularly for its work in pancreatic cancer. Its collaboration with the Cancer Research Center of Marseille – which brings together 23 teams and 14 scientific platforms – will be strengthened with the upcoming opening of the Fight Cancer building, co-funded by the Region to the tune of €3 million (approximately $3.2 million USD).
A new international center of excellence is planned near the current site to focus on cancers with poor prognoses, integrate artificial intelligence into diagnostics, and accelerate the development of new therapies. The Region has already invested over €16 million (approximately $17.2 million USD) in direct support of oncology and the IPC, including the Cancer 21 program, the structuring of the Cancéropôle, expansion of the research center, creation of therapeutic innovation units, acquisition of an IRM accelerator, renovation of patient accommodations, and European FEDER funding for a “health data warehouse” dedicated to research.
Empowering Science to Achieve Victories
In conclusion, Renaud Muselier emphasized the collaborative dynamic between the IPC, researchers, healthcare professionals, and public institutions. He stated that the Institut Paoli-Calmettes embodies a place where “cancer research is advancing the fastest,” serving a dual imperative: enabling scientific progress and giving patients hope.
The Editorial Team
